Klinik für Urologie und Kinderurologie

Studien zur Erkrankung der Prostata

A Phase II, Open-label, Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination With Durvalumab and in Combination With Cabazitaxel and Durvalumab in Patients Who Have Progressive Metastatic Castrate-Resistant Prostate Cancer (AARDVARC)

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of
radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients
with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing
on/after one line of NAH.

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib Maintenance in mCRPC Patients with Homologous Recombination Repair Gene Alterations after Docetaxel Treatment

Studien-Status: wird geöffnet

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

Phase 3 study investigating the efficacy and safety of TAVT-45 (abiraterone acetate) Granules for Oral Suspension (a novel abiraterone acetate formulation) relative to a reference abiraterone acetate formulation in patients with metastatic Castrate Sensitive Prostate Cancer (mCSPC) and metastatic Castrate Resistant Prostate Cancer (mCRPC)

Studien-Status: wird geöffnet

TREATMENT RESISTANCE FOLLOWING ANTI-CANCER THERAPIES (TRANSLATE)

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

 
 
 
 

Kontakt

Barbara Thielen (Ltd. study nurse)
Ansgar Nehus (study nurse)
Michael Grenzebach (study nurse)
Anika Kunz (study nurse)

Terminvereinbarung
Telefonisch: Montag bis Freitag: 10 - 14 Uhr
unter: +49 (0)251- 83 48 12 6
Per E-Mail: uroonkologie(at)­ukmuenster(dot)­de

IN NOTFÄLLEN
T +49 (0)251- 83 47 44 6 oder
T +49 (0)251- 83 48 00 1

Dr. med. Katrin Schlack, FEBU
OA für den Bereich Uroonkologie
Prüfärztin
E-Mail: Katrin.Schlack(at)­ukmuenster(dot)­de